STAT+ R&D Performance Ranking: Insights for Pharma Companies

STAT+ has launched a new ranking of pharmaceutical companies by R&D performance, offering a structured plan for benchmarking who is actually delivering on the promise of their pipelines. For business development teams, investors, and C-suite executives, the ranking provides a data-driven lens for evaluating partnership targets, competitive threats, and capital allocation in an industry where R&D productivity remains under intense scrutiny. Here's what the ranking reveals — and what it means for deal strategy in 2026 and beyond.

Key Takeaways

A handful of companies dominate the top tier — driven by higher clinical trial success rates, faster speed to market, and focused pipeline innovation in high-value therapeutic areas like oncology and metabolic disease.
R&D investment concentration is increasing. Leading firms are doubling down on specific therapeutic areas rather than diversifying broadly, a trend with significant implications for partnership and licensing strategy.
Late-phase attrition remains the single biggest drag on returns. Despite growing R&D spend, the share of compounds that survive from Phase I to approval has not materially improved, reinforcing the need for disciplined portfolio prioritization.
The ranking introduces a new benchmarking tool for BD teams to identify complementary partners — pairing biotechs with novel platform technologies with large pharma companies that have late-stage development and commercialization infrastructure.

What Happened?

On May 19, 2026, STAT published a first-of-its-kind ranking of pharmaceutical companies based on R&D performance, assessing firms across multiple dimensions including clinical trial success rates, speed to market, and pipeline innovation.¹ The effort arrives at a moment when the broader pharma industry is grappling with a well-documented productivity problem. According to Clarivate analysis, R&D productivity fell in 2022 even as total spend continued to climb, with late-phase cancellations only recently showing signs of improvement.²

The STAT+ ranking does not simply rank companies by total R&D expenditure. Instead, it attempts to measure output relative to input — a distinction that matters enormously for investors and BD leaders evaluating whether a company's pipeline spending is translating into approved products and revenue. The data from the International Federation of Pharmaceutical Manufacturers & Associations underscores the challenge: the average time from clinical trial start to patient enrollment close increased 26% between 2019 and 2023, reflecting growing trial complexity.³

Industry outlooks from ZS and PwC both point to 2026 as a potential inflection point, with leading companies reorganizing around five key priorities including AI-driven discovery, streamlined clinical operations, and portfolio discipline.⁴ The STAT+ ranking provides empirical grounding for those strategic narratives — separating companies that have actually restructured their R&D engines from those that have merely announced the intention to do so.

What Does It Mean for Pharma BD and Regulatory Teams?

For business development professionals, the ranking functions as both a screening tool and a negotiation asset. Companies that rank highly on R&D performance metrics are likely to command premium valuations in licensing deals and may be more selective about partnership structures. Conversely, mid-tier or lower-ranked companies with promising individual assets could represent opportunistic in-licensing targets — particularly if their underperformance reflects organizational or executional issues rather than flawed science.

Regulatory teams should pay close attention to the speed-to-market dimension of the ranking. The FDA and EMA have both signaled a willingness to accelerate review timelines for breakthrough therapies and areas of unmet need. Companies that have internalized adaptive trial design, real-world evidence generation, and early regulatory engagement are likely to appear at the top of the ranking — and to maintain that advantage as regulators continue to refine expedited pathways.⁵⁶

Investors, meanwhile, can use the ranking to pressure-test management narratives. A company that publicly emphasizes R&D transformation but ranks poorly on objective performance metrics may warrant deeper due diligence — particularly around Phase II-to-III transition rates, which historically represent the steepest attrition point in drug development. The SEC's increasing focus on material risk disclosures in annual filings (Form 10-K) means that R&D pipeline risks are receiving more rigorous scrutiny from an investor-protection standpoint.⁷

The therapeutic-area concentration trend flagged by the ranking also carries strategic weight. Companies heavily weighted toward GLP-1 metabolic drugs, for example, face both outsized reward and concentrated regulatory and competitive risk as the market matures. BD teams building diversified pipelines may find the ranking useful for identifying partners with complementary therapeutic strengths — balancing oncology-heavy portfolios with CNS or immunology assets, for instance.

What Should Executives Watch Next?

The STAT+ ranking is a snapshot, not a verdict. Its real value will be proven through longitudinal tracking — whether the same companies maintain their positions over multiple annual iterations, or whether strategic shifts produce measurable movement. Executives should watch for three signals in the coming quarters: updates to the ranking methodology as STAT+ refines its approach; responses from companies that rank below expectations, particularly any announced R&D restructuring or leadership changes; and deal activity that correlates with ranking positions, which would validate the framework as a predictor of partnership behavior.

Clinical trial registrants on ClinicalTrials.gov offer a real-time check on whether top-ranked companies are initiating trials at the pace their scores suggest — providing BD teams with an independent data layer to cross-reference against the STAT+ analysis.⁸

Frequently Asked Questions

How does the STAT+ R&D ranking differ from other pharma rankings?

Most pharma rankings sort companies by revenue, market capitalization, or total R&D spend. The STAT+ ranking attempts to measure R&D output efficiency — success rates, speed to market, and pipeline innovation — relative to investment. That distinction makes it more useful for BD and investment decision-making, where the question is not how much a company spends but how effectively it converts spending into approved products.

Which therapeutic areas are most represented among top-ranked companies?

Oncardia and metabolic disease (including GLP-1 receptor agonists) are heavily represented among the top performers, reflecting both the clinical success rates and commercial returns in these areas. However, the ranking also rewards companies with innovative pipelines in smaller or emerging therapeutic categories where first-mover advantages can be significant.

Can the ranking predict future deal activity?

Not directly — but it provides a signal. Companies with high R&D performance scores are likely to be more selective partners in licensing negotiations, while lower-ranked companies with strong individual assets may be more open to creative deal structures including option-based agreements, milestone-heavy terms, or co-development arrangements. BD teams should use the ranking as one input alongside scientific diligence and market analysis.

How often will the STAT+ ranking be updated?

STAT has not publicly committed to an update cadence. Given the pace of clinical trial readouts, regulatory approvals, and pipeline changes, an annual update would be the minimum frequency needed to maintain relevance. Quarterly or semi-annual updates would increase the ranking's utility for real-time deal sourcing and competitive intelligence.

Where can I find the full methodology?

The full ranking and methodology details are available in the STAT+ article published on May 19, 2026.¹ Given that STAT+ operates behind a paywall, BD and investor teams may need a subscription to access the complete dataset and company-by-company breakdowns.

This analysis is based on publicly available reporting and industry data. Rankings and performance metrics are those published by STAT+ and cited sources. Readers should conduct independent due diligence before making investment or partnership decisions.